Scarica l'app Stockscreener
2.44
3.56%
-0.09
Dopo l'orario di chiusura:
2.49
0.05
+2.05%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EDIT Giù?
Forum
Previsione
Precedente Chiudi:
$2.53
Aprire:
$2.55
Volume 24 ore:
1.76M
Relative Volume:
0.72
Capitalizzazione di mercato:
$238.19M
Reddito:
$32.31M
Utile/perdita netta:
$-237.09M
Rapporto P/E:
-0.8472
EPS:
-2.88
Flusso di cassa netto:
$-219.11M
1 W Prestazione:
+0.83%
1M Prestazione:
-6.15%
6M Prestazione:
+23.86%
1 anno Prestazione:
+69.44%
Intervallo 1D:
$2.40
$2.57
Intervallo di 1 settimana:
$2.36
$2.70
Portata 52W:
$0.9101
$4.5372
Editas Medicine Inc Stock (EDIT) Company Profile
Nome
Editas Medicine Inc
Settore
Industria
Telefono
617-401-9000
Indirizzo
11 HURLEY ST., CAMBRIDGE, MA
Confronta EDIT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
2.44 | 246.98M | 32.31M | -237.09M | -219.11M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-28 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-16 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-12-13 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | Downgrade | Stifel | Buy → Hold |
| 2024-12-13 | Downgrade | Truist | Buy → Hold |
| 2024-12-11 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-11-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-11-04 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-05-09 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-10-18 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-10-17 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | Aggiornamento | Stifel | Hold → Buy |
| 2023-06-12 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-13 | Iniziato | Citigroup | Neutral |
| 2022-12-06 | Ripresa | Credit Suisse | Neutral |
| 2022-11-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-09-29 | Iniziato | BofA Securities | Neutral |
| 2021-10-19 | Iniziato | SVB Leerink | Mkt Perform |
| 2021-09-24 | Iniziato | Stifel | Hold |
| 2021-09-10 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-08-09 | Aggiornamento | Truist | Hold → Buy |
| 2021-08-05 | Aggiornamento | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | Iniziato | Goldman | Sell |
| 2021-03-22 | Iniziato | Credit Suisse | Outperform |
| 2021-03-01 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-02-26 | Downgrade | Truist | Buy → Hold |
| 2021-01-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | Iniziato | Robert W. Baird | Underperform |
| 2020-06-18 | Ripresa | SunTrust | Buy |
| 2020-02-21 | Iniziato | Wells Fargo | Equal Weight |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-10-10 | Iniziato | Guggenheim | Neutral |
| 2018-09-21 | Iniziato | Raymond James | Outperform |
| 2018-05-15 | Reiterato | Chardan Capital Markets | Buy |
| 2018-02-13 | Iniziato | CLSA | Underperform |
| 2018-01-23 | Aggiornamento | SunTrust | Hold → Buy |
| 2017-07-14 | Iniziato | SunTrust | Hold |
| 2017-03-28 | Iniziato | Chardan Capital Markets | Buy |
| 2016-08-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2016-06-02 | Iniziato | Jefferies | Hold |
| 2016-02-29 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-02-29 | Iniziato | JP Morgan | Neutral |
| 2016-02-29 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Editas Medicine Inc Borsa (EDIT) Ultime notizie
What analysts say about Editas Medicine Inc stockTechnology Stock Trends & Small Budget Trading Plans - earlytimes.in
Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound? - sharewise.com
Cell & Gene Therapy Market to Reach USD 105.83 Billion by 2033 - openPR.com
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Editas Medicine (EDIT) Price Target Increased by 22.78% to 4.95 - Nasdaq
Editas Medicine (EDIT) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Editas Medicine (NASDAQ:EDIT) CEO Sells $12,046.45 in Stock - MarketBeat
Trend Recap: Is Editas Medicine Inc. (8EM) stock supported by free cash flowJuly 2025 Patterns & High Accuracy Swing Trade Signals - moha.gov.vn
What valuation ratios show for Editas Medicine Inc. (8EM) stockEarnings Summary Report & Reliable Intraday Trade Alerts - Newser
CEO O'Neill Surrenders 5,603 Of Editas Medicine Inc [EDIT] - TradingView
Editas Medicine CEO Sells Shares to Meet Tax Obligations - TradingView
How Editas Medicine Inc. (8EM) stock performs in easing cyclesJuly 2025 Selloffs & Safe Entry Momentum Tips - Newser
Editas Medicine (NASDAQ:EDIT) Shares Cross Below 50-Day Moving AverageTime to Sell? - MarketBeat
Will Editas Medicine Inc. (8EM) stock beat Nasdaq index returns2025 Pullback Review & Free Verified High Yield Trade Plans - Newser
Is Editas Medicine Inc. (8EM) stock positioned for digital growth eraMarket Growth Summary & Free Fast Gain Swing Trade Alerts - Newser
CEO O'Neill Files To Sell 7,000 Of Editas Medicine Inc [EDIT] - TradingView
Euro India Fresh Foods Limited Forms Bullish Flag Upside AheadCovered Call Writing & Learn From the Strategies of Institutions - earlytimes.in
FY2025 EPS Estimates for Editas Medicine Lowered by Analyst - MarketBeat
Editas Medicine (NASDAQ:EDIT) Stock Crosses Below 50-Day Moving AverageTime to Sell? - MarketBeat
Portfolio Shifts: Is Editas Medicine Inc. stock a bargain at current levelsMarket Activity Recap & Fast Moving Stock Trade Plans - moha.gov.vn
Can Editas Medicine Inc. stock surprise with earnings upsideTrade Signal Summary & Fast Gain Stock Tips - moha.gov.vn
Editas Medicine Inc Stock Analysis and ForecastGeopolitical Risk Analysis & Access Free Risk Analysis Before You Invest - earlytimes.in
Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates - MSN
Editas Medicine price target raised to $4.60 from $4 at Clear Street - MSN
Is Editas Medicine Inc. (8EM) stock overpriced at current multiplesPortfolio Risk Report & Risk Controlled Swing Trade Alerts - newser.com
Is Editas Medicine Inc. (8EM) stock in buy zone after pullbackJuly 2025 Rallies & AI Powered Market Entry Strategies - newser.com
Will Editas Medicine Inc. (8EM) stock gain from green policies2025 Big Picture & Technical Confirmation Alerts - newser.com
Will Editas Medicine Inc. stock continue upward momentumForecast Cut & Free Technical Pattern Based Buy Signals - newser.com
How Editas Medicine Inc. (8EM) stock responds to job market shiftsJuly 2025 Snapshot & AI Enhanced Market Trend Forecasts - newser.com
Can Editas Medicine Inc. stock sustain market leadershipQuarterly Risk Review & Weekly Chart Analysis and Trade Guides - newser.com
Is Editas Medicine Inc. (8EM) stock expanding market penetrationFed Meeting & High Accuracy Swing Entry Alerts - newser.com
Does Editas Medicine Inc. (8EM) stock trade below intrinsic valueQuarterly Performance Summary & Verified Chart Pattern Trade Signals - newser.com
Why Is Editas (EDIT) Down 16.9% Since Last Earnings Report? - MSN
Is Editas Medicine Inc. stock a smart buy before Fed meetingWeekly Trading Summary & Stock Portfolio Risk Management - newser.com
Should you hold or exit Editas Medicine Inc. nowPortfolio Risk Summary & Verified Short-Term Trading Plans - newser.com
Editas Medicine Inc Azioni (EDIT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):